HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 4, April 2016 – Leading-Edge ONCOLOGY       » Is Colorectal Carcinomas due to 'Bad Luck' or Is It Preventable?       » Cancer of the Cervix — Can It be Prevented?       » Geriatric Oncology - Featuring Dr. Ravindran Kanesvaran, President of the Singapore Society of Oncology (SSO)       » Discovery Paves the Way for Potential Genetics-Guided Precision Medicine for Paediatric Leukaemia Patients       » China-U.S. Team Uses Stem Cells in Cataract Treatment       » ASLAN - Transforming the Treatment for Rare Tumour Types in Asia       » Using Saltidin to Guard Against the Zika Virus      
BIOBOARD - SINGAPORE
Global threat of multi-drug-resistant Tuberculosis
Veredus Laboratories, a leading supplier of innovative molecular diagnostic tools, has launched VereMTBTM, a multiplexed molecular diagnostic chip capable of fast and accurate detection of Mycobacterium Tuberculosis Complex (MTBC) and its mutations, as well as 9 other clinically relevant non-tuberculous mycobacterium. These mutations are responsible for resistance to multiple drugs and are reinvigorating the global spread of Tuberculosis.

The rise of multi-drug-resistant Tuberculosis (TB) is a global healthcare challenge. Effective treatment of TB involves accurate and fast diagnosis followed by a strict regimen of the right drugs. Shortcomings in this treatment can cause the TB infection to mutate into drugresistant strains that can become increasingly difficult and expensive to treat. Conventional methods of accurately identifying TB infections can take up to 8 weeks. In contrast, VereMTB can complete the diagnosis and identify the specific mycobacterium causing the infection and drug resistance in less than 3 hours from natural samples*, avoiding the need for culturing, the most time-consuming part of the traditional method. Additionally due to its compact size, the system can be deployed in a wide range of settings at point-of-need.

“In 2011, 8.7 million people were diagnosed with TB and 1.4 million people died from the disease. With its ranking by the World Health Organization as the second greatest killer from a single infectious agent worldwide, faster diagnosis and appropriate treatment of this highly infectious disease is critical,” said Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories. “We believe VereMTB fulfills a crucial need in the timely diagnosis of TB and its multi-drug resistance thus ensuring proper treatment.”

The VereMTB multiplexed molecular diagnostic Lab-on-Chip was designed and tested through the TM-REST** program, as part of the European 7th Framework to develop new diagnostics to fight TB and malaria.

“STMicroelectronics is at the forefront of creating silicon technology targeted at healthcare applications,” said Francois Guibert, Executive VP & President, Greater China & South Asia, STMicroelectronics. “Our sensor and power-related technologies have enabled numerous innovations in healthcare, ranging from personal and portable to miniaturized and minimally invasive devices. Using ST's Lab-on-Chip technology, VereMTB is a clear demonstration of ST's ability to leverage its technology portfolio as a strategic solution to address a global healthcare burden.”

Based on STMicroelectronics’ industry-proven Lab-on-Chip technology, the VereMTB chip is currently undergoing evaluations by the Chinese Center for Disease Control and Prevention in Beijing, China as part of their ongoing program to assess new technologies for TB diagnostics. According to the 2012 World Health Organization report on TB, India and China combined have almost 40 percent of the world's TB cases, and nearly 60% of multi-drug resistant cases in 2011 were in India, China, and the Russian Federation.

“At the main CDC National TB Reference Lab in Beijing, we have been evaluating VereMTB using samples, collected from across China with a special interest in detecting challenging multi-drug resistant strains that are difficult to detect using other methods,” said Professor Zhao Yanlin Director of National TB Reference Laboratory and Vice Director of the National Center for Tuberculosis Control and Prevention at the Chinese Center for Disease Control and Prevention. “The speed, accuracy and comprehensiveness of the results have been very promising. We look forward to continuing our collaboration with Veredus for new breakthroughs in diagnosing TB.”

Click here for the complete issue.

NEWS CRUNCH  
news World Immunisation Week 2016
news IoT Asia 2016 Delivers Actionable Solutions for a Sustainable IoT Ecosystem in Asia
news Lite-On presents a new Biomedical Research and Development Centre in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Animated Introduction to Cancer Biology (Full Documentary)
COLUMNS  

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Food Technology
December:
Biomedical Imaging
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy